2000
Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen W, Zhao S, Burke T, Zabinski R, Makuch R, Maurath C, Agrawal N, Geis G. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. The Journal Of Rheumatology 2000, 27: 1876-83. PMID: 10955327.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal PainAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDigestive SystemDouble-Blind MethodDyspepsiaFemaleHumansIsoenzymesMaleMembrane ProteinsMiddle AgedNaproxenNauseaOsteoarthritisProspective StudiesProstaglandin-Endoperoxide SynthasesPyrazolesRisk FactorsSulfonamidesTime FactorsTreatment OutcomeConceptsUpper gastrointestinal tolerabilityUpper GI symptomsSevere abdominal painComposite endpointAbdominal painGastrointestinal tolerabilityGI symptomsIndependent predictorsRheumatoid arthritisRelative riskCOX-2-specific inhibitorsUpper GI tolerabilityTreatment group patientsDose-response relationshipGI tolerabilityPlacebo patientsGroup patientsCumulative incidenceParallel groupClinical trialsPlaceboPatientsCelecoxibTolerabilityEndpoint
1986
Serial determinations of glutathione levels and glutathione-related enzyme activities in human tumor cels in vitro
Batist G, Behrens B, Makuch R, Hamilton T, Katki A, Louie K, Myers C, Ozols R. Serial determinations of glutathione levels and glutathione-related enzyme activities in human tumor cels in vitro. Biochemical Pharmacology 1986, 35: 2257-2259. PMID: 3827990, DOI: 10.1016/0006-2952(86)90601-5.Peer-Reviewed Original ResearchCombined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up.
Winkler C, Sausville E, Ihde D, Fischmann A, Schechter G, Kumar P, Nibhanupdi J, Minna J, Makuch R, Eddy J. Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up. Journal Of Clinical Oncology 1986, 4: 1094-100. PMID: 3088220, DOI: 10.1200/jco.1986.4.7.1094.Peer-Reviewed Original ResearchConceptsTotal skin electron beam irradiationStage I patientsCutaneous T-cell lymphomaDisease-free survivalT-cell lymphomaI patientsStage IIComplete responseModality treatmentCell lymphomaStage IMedian disease-free survivalDisease-free survivorsThree-drug regimensCombined modality treatmentAdvanced-stage patientsOverall response rateOral corticosteroidsAdvanced diseaseSystemic chemotherapyProtocol treatmentTopical therapyStage patientsCR rateSimultaneous chemotherapyNon-small-cell lung cancer. Major cause of late mortality in patients with small cell lung cancer
Johnson B, Ihde D, Matthews M, Bunn P, Zabell A, Makuch R, Johnston-early A, Cohen M, Glatstein E, Minna J. Non-small-cell lung cancer. Major cause of late mortality in patients with small cell lung cancer. The American Journal Of Medicine 1986, 80: 1103-1110. PMID: 3014875, DOI: 10.1016/0002-9343(86)90672-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultCarcinomaCarcinoma, Small CellFemaleHumansLung NeoplasmsMaleMiddle AgedRadiographyTime FactorsConceptsSmall cell lung cancerCell lung cancerLung cancer deathsLung cancerCancer deathSame lobeSecond primary lung tumorsCancer-free survivorsDisease-free survivalPrimary lung tumorsSecond malignant tumorsRisk of developmentLate mortalityContralateral lungTherapeutic trialsInitial lesionLung tumorsMalignant tumorsHigh riskPatientsCancerDifferent lobesMajor causeDiagnosisStudy of men
1985
Effects of fractionated irradiation of endocrine aspects of testicular function.
Shapiro E, Kinsella T, Makuch R, Fraass B, Glatstein E, Rosenberg S, Sherins R. Effects of fractionated irradiation of endocrine aspects of testicular function. Journal Of Clinical Oncology 1985, 3: 1232-9. PMID: 3928830, DOI: 10.1200/jco.1985.3.9.1232.Peer-Reviewed Original ResearchConceptsDose-dependent increaseGerm cell depletionCell depletionTesticular functionBaseline levelsFollicle-stimulating hormone valuesTotal testosterone valuesSerum FSH levelsMedian differenceLeydig cell dysfunctionSoft tissue sarcomasSerum follicle-stimulating hormone (FSH) valuesLeydig cell functionHigh-dose radiationLH changesTubule injuryFSH levelsOnly patientsSerum FSHLH concentrationsTesticular doseHormonal alterationsHormone valuesTumor bedRadiation injuryThe role of radiation therapy in the treatment of small cell lung cancer
Lichter A, Bunn P, Ihde D, Cohen M, Makuch R, Carney D, Johnston‐Early A, Minna J, Glatstein E. The role of radiation therapy in the treatment of small cell lung cancer. Cancer 1985, 55: 2163-2175. PMID: 2983875, DOI: 10.1002/1097-0142(19850501)55:9+<2163::aid-cncr2820551420>3.0.co;2-y.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsCarcinoma, Small CellClinical Trials as TopicCombined Modality TherapyCyclophosphamideDoxorubicinFollow-Up StudiesHumansLomustineLung NeoplasmsMethotrexateProcarbazineProspective StudiesRadiotherapyRadiotherapy DosageRandom AllocationTime FactorsVincristineWhole-Body IrradiationConceptsSmall cell lung cancerLimited-stage small cell lung cancerProphylactic cranial irradiationCell lung cancerCranial irradiationThoracic irradiationLung cancerExtensive-stage small-cell lung cancerComplete response statusLimited-stage diseaseOptimal treatment approachCombination of chemotherapyMinimum of toxicityLong-term survivalSystemic irradiationSystemic chemotherapyAggressive therapyPartial responseCNS failureResponse statusTreatment protocolOngoing protocolRadiation therapyTreatment approachesPatientsActuarial risk of isolated cns involvement in Ewing's sarcoma following prophylactic cranial irradiation and intrathecal methotrexate
Trigg M, Makuch R, Glaubiger D. Actuarial risk of isolated cns involvement in Ewing's sarcoma following prophylactic cranial irradiation and intrathecal methotrexate. International Journal Of Radiation Oncology • Biology • Physics 1985, 11: 699-702. PMID: 3838542, DOI: 10.1016/0360-3016(85)90300-1.Peer-Reviewed Original ResearchConceptsEwing's sarcomaIntrathecal methotrexateCNS irradiationProphylactic cranial irradiationGroup of patientsCurrent treatment regimensLack of efficacyNational Cancer InstituteCranial irradiationInitial therapyCNS involvementCNS recurrenceTreatment regimensCNS treatmentIrradiation regimenCancer InstituteActuarial riskSarcomaOverall riskPatientsTherapyMethotrexateRiskCNSInvolvementPrognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival
Ihde D, Matthews M, Makuch R, McIntire K, Eddy J, Seeff L. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Identification of two groups of patients with prospects for prolonged survival. The American Journal Of Medicine 1985, 78: 399-406. PMID: 2579551, DOI: 10.1016/0002-9343(85)90330-4.Peer-Reviewed Original ResearchConceptsAlpha-fetoprotein levelsFibrolamellar carcinomaHepatocellular carcinomaSystemic chemotherapyNormal serum alpha-fetoprotein levelsHepatitis B serum markersNormal alpha-fetoprotein levelsSerum alpha-fetoprotein levelsElevated alpha-fetoprotein levelsAmbulatory performance statusHomogeneous clinical featuresAbsence of cirrhosisHepatitis B markersTime of diagnosisGroup of patientsInitiation of treatmentLack of jaundiceAmbulatory statusExtrahepatic metastasesPerformance statusImproved survivalIndolent coursePrognostic factorsClinical featuresSerum markers
1983
Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer Potential benefit restricted to patients with complete response
Rosen S, Makuch R, Lichter A, Ihde D, Matthews M, Minna J, Glatstein E, Bunn P. Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer Potential benefit restricted to patients with complete response. The American Journal Of Medicine 1983, 74: 615-624. PMID: 6301274, DOI: 10.1016/0002-9343(83)91019-7.Peer-Reviewed Original ResearchConceptsCentral nervous system metastasesProphylactic cranial irradiationNervous system metastasesCranial irradiationComplete responsePrognostic featuresSystemic therapyCentral nervous system relapseSmall cell lung cancerInvolvement of liverPercent of patientsNervous system relapseSystemic combination chemotherapySubset of patientsTwo-year survivalCell lung cancerStage of diseaseCentral nervous systemNational Cancer InstituteChest irradiationComplete remissionEpidural metastasesOverall survivalCombination chemotherapyIntracerebral metastases
1982
Sample size requirements for comparing time-to-failure among k treatment groups
Makuch R, Simon R. Sample size requirements for comparing time-to-failure among k treatment groups. Journal Of Clinical Epidemiology 1982, 35: 861-867. PMID: 7142364, DOI: 10.1016/0021-9681(82)90051-0.Peer-Reviewed Original Research
1981
Adjuvant Immunotherapy or Chemotherapy for Malignant Melanoma: Preliminary Report of the National Cancer Institute Randomized Clinical Trial
Fisher R, Terry W, Hodes R, Rosenberg S, Makuch R, Gordon H, Fisher S. Adjuvant Immunotherapy or Chemotherapy for Malignant Melanoma: Preliminary Report of the National Cancer Institute Randomized Clinical Trial. Surgical Clinics Of North America 1981, 61: 1267-1277. PMID: 7031934, DOI: 10.1016/s0039-6109(16)42582-x.Peer-Reviewed Original ResearchConceptsBacille Calmette-GuerinDisease-free intervalAdjuvant immunotherapyClinical trialsMalignant melanomaStage I malignant melanomaStage II melanomaSurvival of patientsNational Cancer InstituteOverall survivalPostsurgical patientsMethyl-CCNUCalmette-GuerinCancer InstituteMelanoma cellsMelanomaFurther treatmentPreliminary reportImmunotherapyChemotherapyPatientsTrialsSurvivalSignificant improvementLaboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer.
Cohen M, Makuch R, Johnston-Early A, Ihde D, Bunn P, Fossieck B, Minna J. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Journal Of The National Cancer Institute 1981, 65: 187-95. PMID: 6263468.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerCell lung cancerLaboratory parametersLung cancerPerformance statusPrognostic factorsPrognostic indexSmall cell anaplastic lung cancerInfluential prognostic factorObjective prognostic indexPretreatment performance statusMajor prognostic factorSelf-limited eventAlpha-1 globulinCancer clinical trialsLaboratory resultsSignificant prognosticatorMedian followupAlbumin levelsMinimum followupPrognostic stratificationSurvival durationClinical trialsHigher hemoglobinTreatment response
1980
Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma
Glaubiger D, Makuch R, Schwarz J, Levine A, Johnson R. Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma. Cancer 1980, 45: 2213-2219. PMID: 7370962, DOI: 10.1002/1097-0142(19800415)45:8<2213::aid-cncr2820450834>3.0.co;2-l.Peer-Reviewed Original ResearchConceptsDisease-free survivalPrognostic factorsEwing's sarcomaTreatment groupsLactic acid dehydrogenasePrimary diseaseSerum lactic acid dehydrogenaseSystemic chemotherapy regimensFavorable prognostic factorTime of presentationLactic acid dehydrogenase levelsNumber of patientsResults of treatmentNational Cancer InstituteLatest regimensChemotherapy regimensMetastatic diseaseFavorable prognosisMetastatic statusFavorable outcomeTherapeutic resultsDehydrogenase levelsTreatment protocolLocal irradiationCancer Institute
1979
EFFECTS OF THYMOSIN IN VITRO IN CANCER PATIENTS AND CORRELATION WITH CLINICAL COURSE AFTER THYMOSIN IMMUNOTHERAPY
Chretien P, Lipson S, Makuch R, Kenady D, Cohen M. EFFECTS OF THYMOSIN IN VITRO IN CANCER PATIENTS AND CORRELATION WITH CLINICAL COURSE AFTER THYMOSIN IMMUNOTHERAPY. Annals Of The New York Academy Of Sciences 1979, 332: 135-147. PMID: 316979, DOI: 10.1111/j.1749-6632.1979.tb47107.x.Peer-Reviewed Original Research